Rosacea: Complete Management Guide

What is Rosacea?

Rosacea is a common chronic inflammatory condition affecting 1-5% of the population, with higher prevalence in fair-skinned individuals of Celtic or Northern European descent. Characterized by episodic or persistent facial flushing, erythema (redness), telangiectasia (visible blood vessels), and sometimes acne-like inflammatory papules and pustules. Typically begins in third-to-fourth decades of life. Predominantly affects face; can involve eyes, scalp, ears, neck, and trunk in some patients. Profoundly impacts quality of life through cosmetic concerns and symptoms.

Rosacea Subtypes

Subtype 1 (Vascular)

Characterized by flushing and persistent facial erythema with telangiectasia. Typically involves central face (cheeks, nose, glabella, chin). Acne-like lesions absent. Most common presentation.

Subtype 2 (Inflammatory Acne-Rosacea)

Features persistent erythema with inflammatory papules, pustules, and sometimes nodules. Comedones notably absent (distinguishing from acne vulgaris). Often associated with perioral and perinasal distribution.

Subtype 3 (Phymatous)

Characterized by thickening and irregular contours from tissue hypertrophy. Rhinophyma (nasal involvement) represents most common presentation. Results from chronic dilation of blood vessels and connective tissue overgrowth.

Ocular Involvement

Present in 20-50% of rosacea patients; may precede facial manifestations. Presents with dry eye, foreign body sensation, redness, and grittiness. Posterior blepharitis with meibomian gland dysfunction drives ocular inflammation.

Disease Mechanism

Rosacea involves vascular hyperreactivity, abnormal inflammatory responses, and potential antimicrobial dysregulation. Dysregulation of innate immune system (TLR and NOD-like receptors) drives excessive responses to triggers. Cathelicidin (antimicrobial peptide) dysregulation may increase susceptibility to Demodex mites, which trigger Th17-mediated inflammation. Increased vascular tone and abnormal vascular response to heat/triggers produces characteristic flushing and erythema. The precise etiology remains incompletely understood; multiple mechanisms likely contribute.

Common Triggers

Temperature: Heat (hot beverages, hot water exposure, warm environments, sauna) is most common trigger for flushing. Cold exposure causes reactive erythema. Foods: Spicy foods (capsaicin), hot foods, alcohol (particularly red wine), caffeine trigger flares. Stress: Emotional stress exacerbates 60-70% of cases through neuroimmune mechanisms. Skin Irritants: Harsh cleansers, astringent products, corticosteroid overuse perpetuate flares. Climate: Wind exposure, UV radiation, low humidity worsen disease. Medications: Topical corticosteroid withdrawal (steroid-induced rosacea), some vasodilators.

Diagnosis

Diagnosis is clinical, based on facial pattern of erythema and presence of characteristic findings without comedones. Standard Rosacea Diagnostic Criteria require persistent flushing or erythema in central face plus one of: visible blood vessels, inflammatory papules/pustules/nodules, or ocular manifestations. Dermoscopy reveals dilated vessels. Biopsy generally unnecessary unless diagnosis unclear.

Management Approach

Step-wise management begins with trigger identification and avoidance, combined with gentle skin care. Topical anti-inflammatory agents (azelaic acid, metronidazole) address inflammatory component without requiring systemic therapy. Oral antibiotics (doxycycline) provide additional benefit through anti-inflammatory mechanisms beyond antimicrobial effects. Refractory disease warrants consideration of laser/light therapies or systemic agents. Long-term control requires ongoing maintenance therapy as disease tends to be chronic.

Medical Treatments

Topical Agents

Azelaic Acid: First-line agent; reduces inflammatory mediators and suppresses Demodex populations. 15-20% formulations twice daily. Results visible in 4-8 weeks. Well-tolerated; irritation possible. Metronidazole: 0.75-1% formulations; anti-inflammatory effects dominate antimicrobial effects. Twice daily application. Results in 4-8 weeks. Sulfacetamide-Sulfur: Antimicrobial and anti-inflammatory; less frequently prescribed in modern practice.

Oral Antibiotics

Doxycycline: 50mg daily low-dose formulation (Oracea) provides anti-inflammatory benefits at sub-antimicrobial doses. Results in 2-6 weeks. Well-tolerated. Minocycline: Alternative tetracycline option. Azithromycin: Macrolide option for doxycycline-intolerant patients. Requires 3-4 months therapy for full benefit.

Procedural Treatments

Laser/IPL: Target dilated vasculature (pulsed dye laser) or general erythema (IPL). Effective for vascular component; require multiple sessions (4-6). Results cumulative over weeks-to-months. Dermabrasion/Microdermabrasion: Mechanical approaches less effective than laser; risk of triggering flares.

Trigger Management

• Identify personal triggers through symptom tracking
• Avoid temperature extremes; use lukewarm water for cleansing
• Avoid spicy foods, hot beverages, alcohol if triggering
• Manage stress through exercise, meditation, counseling
• Use gentle, fragrance-free cleansers
• Apply non-irritating moisturizer to prevent barrier dysfunction
• Use mineral sunscreen SPF 30+ daily for UV protection
• Avoid overuse of topical corticosteroids; use lowest potency for shortest duration
• For ocular involvement, maintain meibomian gland hygiene with warm compresses and blink exercises

Complications and Monitoring

Phymatous changes (severe nasal involvement) may require surgical reduction for functional and cosmetic improvement. Ocular involvement requires monitoring for blepharitis and potential complications. Depression and anxiety affect 30-40% of rosacea patients due to cosmetic concerns; psychological support beneficial. Rarely, severe uncontrolled disease can affect quality of life significantly; dermatology referral recommended for complex cases.